AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$UTHR

ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.39 ($498.45–$505.20, $4.76M total) across 8 trades on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 17, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The sale represents a $4.8M reduction in insider holdings, which could be interpreted as a negative sentiment cue.

02

Market read

Primary insider sale news with modest materiality.

03

What to watch

Sale executed via pre‑arranged plan, reducing discretionary signal.

Relevance 5/10Novelty 6/10Timing: same-day filing

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.8M of United Therapeutics shares via a 10b5-1 plan on 2026-09-16.

Expected impact

Potential modest dip in near-term trading.

Evidence & confidence

CEO insider sales are viewed as a bearish signal, especially at $500+ price levels.

Market effects

Sector

Minimal impact on biotech sector.

Regional

US market only.

Global

Low

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Company
    United Therapeutics Corp

    Biopharma company listed on NYSE under ticker UTHR.

  • Insider
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min